We are live on ! Find out more
Royal Bank of Canada

Royal Bank of Canada Portfolio holdings

AUM $570B
1-Year Est. Return 27.57%
 

Royal Bank of Canada (RBC), founded in 1864 and headquartered in Toronto, is Canada’s largest bank by market capitalization and one of the leading financial institutions in North America, offering a comprehensive suite of services including personal and commercial banking, wealth management, insurance, and capital markets. Managing hundreds of billions in assets, RBC serves millions of clients globally, with a significant presence in the U.S. and Caribbean through subsidiaries like RBC Wealth Management and City National Bank. Known for its stability and consistent profitability, RBC has earned a reputation as a conservative yet innovative bank, expanding its digital offerings and sustainability initiatives in recent years. With a strong focus on customer service and a robust international footprint, RBC remains a cornerstone of the Canadian and global financial systems.

This Fund
S&P 500
This Quarter Est. Return
+4.82%
1 Year Est. Return
+27.57%
3 Year Est. Return
+75.99%
5 Year Est. Return
+94.97%
10 Year Est. Return
+325.25%
AUM
$228B
AUM Growth
+$19.5B
Cap. Flow
+$9.66B
Cap. Flow %
4.24%
Top 10 Hldgs %
19.68%
Holding
7,447
New
331
Increased
2,461
Reduced
3,156
Closed
486

Sector Composition

Rank Sector Weight
1 Financials 21.58%
2 Energy 8.65%
3 Industrials 8.54%
4 Technology 7.61%
5 Communication Services 7.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARGO
6201
DELISTED
Argo Group International Holdings, Ltd.
ARGO
$2K ﹤0.01%
46
-2,998
-98% -$160K
UBP
6202
DELISTED
Urstadt Biddle Properties Inc.
UBP
$2K ﹤0.01%
100
-1
-1% -$18
IMBI
6203
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
$2K ﹤0.01%
109
-4
-4% -$51
ECOM
6204
DELISTED
CHANNELADVISOR CORPORATION
ECOM
$2K ﹤0.01%
196
-12,153
-98% -$120K
AMPE
6205
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$2K ﹤0.01%
2
+1
+100% +$470
EVFM
6206
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$2K ﹤0.01%
+11
New +$1.24K
LEAF
6207
DELISTED
Leaf Group Ltd.
LEAF
$2K ﹤0.01%
185
-1,181
-86% -$9.25K
GNMK
6208
DELISTED
GenMark Diagnostics, Inc
GNMK
$2K ﹤0.01%
375
-3,908
-91% -$23.5K
EIGI
6209
DELISTED
Endurance International Group Holdings, Inc.
EIGI
$2K ﹤0.01%
249
-4,949
-95% -$41.9K
GMO
6210
DELISTED
General Moly, Inc.
GMO
$2K ﹤0.01%
8,352
+200
+2% +$64
CORV
6211
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2K ﹤0.01%
1,233
-656
-35% -$1.05K
I
6212
DELISTED
INTELSAT S. A.
I
$2K ﹤0.01%
454
-3,502
-89% -$15.6K
SUMR
6213
DELISTED
Summer Infant, Inc.
SUMR
$2K ﹤0.01%
112
+111
+11,100% +$1.58K
GNMX
6214
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2K ﹤0.01%
2,025
BKJ
6215
DELISTED
Bancorp of New Jersey, Inc.
BKJ
$2K ﹤0.01%
108
SDT
6216
DELISTED
SANDRIDGE MISSISSIPPIAN TRUST I
SDT
$2K ﹤0.01%
2,500
FELP
6217
DELISTED
Foresight Energy LP
FELP
$2K ﹤0.01%
450
UQM
6218
DELISTED
UQM Technologies, Inc.
UQM
$2K ﹤0.01%
1,435
+1,400
+4,000% +$1.79K
NAVB
6219
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$2K ﹤0.01%
335
-200
-37% -$1.69K
FFKT
6220
DELISTED
Farmers Capital Bank Corp
FFKT
$2K ﹤0.01%
42
-624
-94% -$25.8K
GCH
6221
DELISTED
Aberdeen Greater China Fund
GCH
$2K ﹤0.01%
187
FOGO
6222
DELISTED
Fogo de Chao, Inc. Common Stock
FOGO
$2K ﹤0.01%
150
-786
-84% -$9.08K
CASC
6223
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2K ﹤0.01%
732
-3,355
-82% -$13.7K
RXDX
6224
DELISTED
Ignyta, Inc.
RXDX
$2K ﹤0.01%
65
-4,333
-99% -$70.4K
SBCP
6225
DELISTED
Sunshine Bancorp, Inc
SBCP
$2K ﹤0.01%
91
-519
-85% -$12.2K

Similar funds

Royal Bank of Canada's Q4 2017 Portfolio in Review

As of Q4 2017, Royal Bank of Canada held 7,447 positions worth $228B, up 9.4% from $208B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Royal Bank of Canada deployed $9.66B of net new capital in Q4 2017, opening 331 new positions and adding to 2,461 existing holdings. Its largest new stake was Maxar Technologies Inc. Common Stock: 2,562,561 shares worth $165M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 22% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $611M trimmed.

  • Royal Bank of Canada's largest Q4 2017 buy was Maxar Technologies Inc. Common Stock: 2,562,561 shares worth $165M.
  • Royal Bank of Canada added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $2.31B increase.
  • Royal Bank of Canada's biggest Q4 2017 reduction was iShares Core S&P 500 ETF, cutting an estimated $611M.
  • Royal Bank of Canada fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $144M.
  • Royal Bank of Canada's ten largest holdings make up 20% of its $228B portfolio in Q4 2017.
  • Royal Bank of Canada opened 331 new positions and closed 486 in Q4 2017.
  • Royal Bank of Canada's portfolio value rose 9.4% quarter-over-quarter to $228B.

Based on Royal Bank of Canada's 13F filing for Q4 2017, filed 14 Feb 2018.